Sanofi-Aventis Canada Inc. v. Teva Canada Limited, 2012 FC 552 (Ramipril*)
Justice Snider - 2012-05-23
Read full decision. Automatically generated summary:
Teva Canada Limited (Teva), the Plaintiff by Counterclaim in this action, sells a generic version of ramipril – a drug used mainly to treat hypertension – into the Canadian market. Sanofi-Aventis Canada Inc. (Sanofi), one of the Defendants by Counterclaim in this action, holds or has held patent rights to a brand-name version of ramipril – ALTACE.
Decision relates to:
- T-1161-07 - SANOFI-AVENTIS CANADA INC. ET AL v. NOVOPHARM LIMITED
- A-147-12(2014 FCA 67) - which is an appeal from this decision
- T-1161-07 - SANOFI-AVENTIS CANADA INC. ET AL v. NOVOPHARM LIMITED
- A-192-12(2014 FCA 69) - which is an appeal from this decision
- T-1161-07 - SANOFI-AVENTIS CANADA INC. ET AL v. NOVOPHARM LIMITED
- A-193-12(2014 FCA 68) - which is an appeal from this decision